These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 15189749

  • 1. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW, Brown SD.
    Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
    Brown SD, Rybak MJ.
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.
    Doern GV, Brown SD.
    J Infect; 2004 Jan; 48(1):56-65. PubMed ID: 14667792
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D.
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
    Kohno S, Hoban D, Protekt Surveillance Study Group.
    J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
    Sunakawa K, Farrell DJ.
    Ann Clin Microbiol Antimicrob; 2007 Aug 13; 6():7. PubMed ID: 17697316
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance].
    Gómez-Garcés JL, Alós JI, Hernáiz C, Gómez C.
    Enferm Infecc Microbiol Clin; 2004 Aug 13; 22(6):323-7. PubMed ID: 15228898
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-5 (1999-2004).
    Inoue M, Farrell DJ, Kaneko K, Akizawa K, Fujita S, Kaku M, Igari J, Yamaguchi K, Yamanaka K, Murase M, Asari S, Hirakata Y, Baba H, Itaha H.
    Microb Drug Resist; 2008 Jun 13; 14(2):109-17. PubMed ID: 18500920
    [Abstract] [Full Text] [Related]

  • 13. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
    Inoue M, Kohno S, Kaku M, Yamaguchi K, Igari J, Yamanaka K.
    Int J Infect Dis; 2005 Jan 13; 9(1):27-36. PubMed ID: 15603993
    [Abstract] [Full Text] [Related]

  • 14. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M, Browne FA, Jacobs MR, Appelbaum PC.
    Clin Ther; 2003 Jan 13; 25(1):169-77. PubMed ID: 12637118
    [Abstract] [Full Text] [Related]

  • 15. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.
    Felmingham D, Reinert RR, Hirakata Y, Rodloff A.
    J Antimicrob Chemother; 2002 Sep 13; 50 Suppl S1():25-37. PubMed ID: 12239226
    [Abstract] [Full Text] [Related]

  • 16. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
    Low DE, Brown S, Felmingham D.
    Clin Microbiol Infect; 2004 Jan 13; 10(1):27-36. PubMed ID: 14706083
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-3 (1999-2002).
    Inoue M, Kaneko K, Akizawa K, Fujita S, Kaku M, Igari J, Yamaguchi K, Kohno S, Yamanaka K, Iinuma Y, Murase M, Yokoyama T, Asari S, Hirakata Y.
    J Infect Chemother; 2006 Feb 13; 12(1):9-21. PubMed ID: 16506084
    [Abstract] [Full Text] [Related]

  • 19. In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program.
    Flamm RK, Rhomberg PR, Sader HS.
    Antimicrob Agents Chemother; 2017 Dec 13; 61(12):. PubMed ID: 28971877
    [Abstract] [Full Text] [Related]

  • 20. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F, Carnegy F, Willcock J, Amyes S.
    J Antimicrob Chemother; 2004 May 13; 53(5):793-6. PubMed ID: 15056640
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.